Two types of vaccine are currently on the market: the polysaccharide vaccine and the conjugated vaccine. The polysaccharide form, elaborated from a sugar present at the surface of the meningococcus provides only partial, temporary immunity in very young children (2).
The conjugated vaccine, however, is based on a combination between this same sugar and an antigenic protein and renders an effective durable immunity. It could therefore be used in a routine preventive vaccination campaign. But it is costly. Its high price, at 11 to 22 euros per dose, means it remains inaccessible for African countries. These have available only the polysaccharide vaccine, less expensive at 0.3 to 0.5 euro, but which, because of its low immunity capacity, is generally kept only for emergency vaccinations, when epidemics occur.
IRD researchers have been running a follow-up study of the people of the Niakhar region (located 150 km from Dakar, in Senegal) for more than 40 years. They looked into the question of the ability of the polysaccharide vaccine to prevent the occurrence of meningitis cases during epidemics in the course of subsequent years. To do that, they made use of results of two vaccination campaigns conducted with this vaccine by the Senegalese health services. One of these was run in 1996 in 8 of the 30 villages that make up the Niakhar region, the other in 1999, in the whole of the study area, hit be a series of epidemics between 1998 and 2000.
Using quarterly censuses carried out since 1983, the researchers collected then analysed data on children’s state of health and vaccine status. They could therefore make comparisons between the different villages regarding the number of cases of meningitis that broke out, in particular in the years that followed the 1996 vaccination campaign (3).
Their investigation revealed that in the villages vaccinated at that date, two to three times fewer subjects were recorded as suffering from the disease. The polysaccharide vaccine could help avoid up to 72% of cases in subsequent epidemics.
These results speak in favour of adopting a strategy of routine vaccination using this vaccine – whenever no other vaccine is available – in order to prevent meningococcus meningitis epidemics in this region of Africa. However, a conjugated vaccine which should be sold at less than 1$ (0.80 euro) per dose, is under development. Thanks to the full, durable immunity it confers right from early childhood, it is an ideal tool for a preventive vaccination strategy. Clinical trials initiated in 2006, notably in Niakhar, are continuing for a further 2 years in order to make sure that no undesirable side-effects occur after administration.
Marie Guillaume | EurekAlert!
New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia
New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
18.08.2017 | Life Sciences
18.08.2017 | Physics and Astronomy
18.08.2017 | Materials Sciences